Observational studyBMC cancer2023

Immune checkpoint inhibitors enhanced the antitumor efficacy of disitamab vedotin for patients with HER2-positive or HER2-low advanced or metastatic gastric cancer: a multicenter real-world study.

Caiyun Nie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.